Literature DB >> 19498405

Prostate cancer: to screen or not to screen?

Urs E Studer, Laurence Collette.   

Abstract

Unfortunately, interim analyses of the long-awaited ERSPC and PLCO trial data have generated conflicting conclusions. Here, two European authors speculate as to the reasons underlying this contradiction, while highlighting clinically relevant points that are supported by both studies. Particular attention is paid to the potential consequences of overdiagnosis and overtreatment.

Entities:  

Mesh：

Year:  2009        PMID： 19498405     DOI： 10.1038/nrurol.2009.92

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  8 in total

1.  It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.

Authors:  Ian M Thompson; Donna P Ankerst; Ruth Etzioni; Thomas Wang
Journal:  J Urol       Date:  2008-08-15       Impact factor: 7.450

2.  Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy.

Authors:  Jonathan I Epstein; Harriete Sanderson; H Ballentine Carter; Daniel O Scharfstein
Journal:  Urology       Date:  2005-08       Impact factor: 2.649

Review 3.  The changing face of prostate cancer.

Authors:  Matthew R Cooperberg; Judd W Moul; Peter R Carroll
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

4.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

5.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

6.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

Authors:  Gerrit Draisma; Rob Boer; Suzie J Otto; Ingrid W van der Cruijsen; Ronald A M Damhuis; Fritz H Schröder; Harry J de Koning
Journal:  J Natl Cancer Inst       Date:  2003-06-18       Impact factor: 13.506

7.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

8.  Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

Authors:  Peter Iversen; Jan-Erik Johansson; Pär Lodding; Olavi Lukkarinen; Per Lundmo; Peter Klarskov; Teuvo L J Tammela; Ilker Tasdemir; Tom Morris; Kevin Carroll
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450
  8 in total
  2 in total

1.  Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials.

Authors:  Elisabeth Eckersberger; Julia Finkelstein; Helen Sadri; Markus Margreiter; Samir S Taneja; Herbert Lepor; Bob Djavan
Journal:  Rev Urol       Date:  2009

Review 2.  Anticancer activity of green tea polyphenols in prostate gland.

Authors:  Pierpaola Davalli; Federica Rizzi; Andrea Caporali; Davide Pellacani; Serena Davoli; Saverio Bettuzzi; Maurizio Brausi; Domenico D'Arca
Journal:  Oxid Med Cell Longev       Date:  2012-05-15       Impact factor: 6.543
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.